Loading...
•
Jul 02, 2022
USANA Q2 2022 Earnings Report
USANA's financial performance declined due to COVID-related disruptions and a tough year-over-year comparison.
Key Takeaways
USANA Health Sciences reported a decrease in net sales and diluted EPS for the second quarter of 2022, primarily due to COVID-related disruptions in key markets, including mainland China. The company is reiterating its fiscal year 2022 outlook for net sales and diluted EPS.
Second quarter net sales were $264 million, compared to $337 million in the prior year.
Diluted EPS for the second quarter totaled $1.00, versus $1.87 in the second quarter of 2021.
The company is reiterating its fiscal 2022 net sales outlook of $1.015 billion to $1.065 billion.
The company is reiterating its fiscal 2022 diluted EPS outlook of $3.85 to $4.45.
Revenue by Geographic Location
Forward Guidance
USANA anticipates a challenging operating environment in the second half of the year, impacted by a lower-than-anticipated Active Customer base. Despite these challenges, they remain committed to their business objectives and will align their cost structure with sales performance.
Positive Outlook
- The company is committed to its business strategy to deliver sustained, long-term growth.
- The company is enhancing digital experience for customers.
- The company is improving Associate onboarding and training.
- The company is exploring additional promotions and incentives on a market-specific basis.
- The company is launching experience centers in mainland China.
Challenges Ahead
- The company continues to experience COVID-related disruptions in several key markets, including mainland China.
- The company faced a tough year-over year comparable due to the timing of a successful sales program in 2021.
- The company believes it will continue to face a challenging operating environment in the second half of the year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...